Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Sep 23, 2025 (13 months ago)

Fentanyl citrate

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Revised interpretation of Acceptable Quality Level (AQL) results.

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Fentanyl citrate, 2 mcg / ml / Ropivacaine, 0.2% in NS 150 mL, CII, 150 mL bag, Rx Only, Park Avenue Compounding, 3662 Park Ave, Saint Louis, MO, 63110, NDC 83863-4272-1.

Affected NDC 83863-4272-01

Compare with the code on your package — it is the most precise check available.

Drug: Fentanyl

Recalling firm
Park Avenue Compounding
NDC code
83863-4272-1
Origin
MO, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0178-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Fentanyl recalls

See all
Class II · Moderate risk

fentaNYL Citrate

Labeling: Not Elsewhere Classified: Complaint received on 08/31/2026 regarding the discrepancy of the IV bag expiry (07/31/2026 and 11/30/2026) and the product expiry (12/09/2026).

Ongoing Labeling / mix-up OurPharma LLC NDC 73013-1013-01 D-0864-2026

Other recalls by Park Avenue Compounding

All 2025 recalls